Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: naratuximab emtansine, bi-836826, otlertuzumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16545
Sealed predictions
- CD37 in dopamine neurons, braak-0.58 (p 0.102) → +0.25 (p 0.520)receipt 16552
Swarm cases
receipt 16552: CD37 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.261, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.45 (p 0.062, n 18). could be the mix.
- skeptic
- leave-one-out range -0.39 to -0.17, sign flips 0; without severely affected donors -0.28 (p 0.261, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.62 (p 0.0064, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD37 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CD37 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.35 p 0.214 (needs p < 1.4e-4)
Receipts
loading the receipts